The MammaPrint © index [88,89], Prosigna ©/PAM50 assay [90] and Breast Cancer Index © [91,92] were also validated as significant predictors of response to neoadjuvant chemotherapy in predominantly HR+/HER2− populations. This evidence concerns the gene ERBB2 and breast carcinoma.